India’s small and medium-sized pharma manufacturers are set to face tighter regulatory scrutiny, with the Central Drugs Standard Control Organisation (CDSCO) directing state authorities to conduct inspections under the revised Schedule M manufacturing norms. The move marks the end...
India’s pharmaceutical sector is seeing significant progress under the Production Linked Incentive (PLI) Scheme for Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs). A total of 48 projects have been approved to strengthen local manufacturing...
